InvestWiser

Prostatype Genomics AB

PROGENNasdaq StockholmHealthcareMarket value 14 m SEK
0.09SEK −6.1%
last day · Price as of 18 November 2026

The answer first

Does Prostatype Genomics beat the market?

No, Prostatype Genomics has not beaten the market over the last year.

Prostatype Genomics−84.2%Stockholm (OMXSGI)+18.4%
  • The ranking · Quality, value and trend combined

    Better than 9% of Nordic stocks

    • Quality20
    • Value55
    • Trend3

    No. 163 of 192 in healthcare

Max for seven days

Follow Prostatype Genomics with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Prostatype Genomics

From today, at a price of 0.09 SEK. Write why you follow Prostatype Genomics, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Prostatype Genomics

Your first answer is free, no account needed.

Do you own Prostatype Genomics, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Prostatype Genomics and a few more. Free, no card.

Past year against the exchange and Super Stock
Prostatype Genomics−84.2%Stockholm (OMXSGI)+18.4%Super Stock+45.9%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Prostatype Genomics has fallen 84.2% over the past year, including dividends.
  • Overall, Prostatype Genomics ranks better than 9% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 99.9%. The price is 100.0% below its peak now.

What do analysts think of Prostatype Genomics?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

9

Quality, value and trend together. Better than 9% of Nordic stocks.

No. 163 of 192 in healthcare

Quality20
The company · Fundamentals: the accounts

Low Weaker accounts than most: low profitability, high debt or uneven results.

No. 169 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.81
  • Asset turnoverSales divided by everything the company owns0.03
  • Return on equityProfit divided by equity−167.7%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value55
The price · Valuation: the multiples

Medium Fair price: about the same as a typical Nordic stock.

No. 40 of 194 in healthcareTypical in healthcare: 19Typical in the Nordics: 50

  • P/BPrice divided by equity0.8
  • P/SPrice divided by sales5.0
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend3
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 185 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−29.2%
  • 6 months−81.4%
  • 9 months−93.1%
  • 12 months−84.2%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−12.2%
3 years, per year
−84.5%
5 years, per year
−84.2%
Year to date
−70.1%
Largest fall, 3 years
−99.9%
From a peak to the bottom
From the peak now
−100.0%
How far the price is from the peak
Volatility, 1 year
199.1%
How much the price swings over a year
Beta, 1 year
0.71
How much the price moves when the market moves

Return with dividends reinvested.

About Prostatype Genomics

Prostatype Genomics AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 7 employees.

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Nacka, Sweden.

See the full analysis of Prostatype Genomics.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market